
Exicure Completes Final Patient Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma
Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial…












